PHAR (Pharming Group) Institutional Ownership: 0.12% (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHAR Pharming Group PHAR
77 GF Score
Price $13.47
GF Value $14.45
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Institutional Ownership?

Pharming Group PHAR +2.98% 77 Institutional Ownership is 0.12% as of Jul. 17, 2026. GuruFocus rates PHAR with a GF Score™ of 77/100 and a GF Value™ of $14.45 (Fairly Valued). The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pharming Group's institutional ownership is 0.12%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pharming Group's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pharming Group's Float Percentage Of Total Shares Outstanding is 99.36%.

Pharming Group Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Pharming Group's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Institutional Ownership Chart

Pharming Group Historical Data

The historical data trend for Pharming Group can be seen below:

2023-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.09 0.02 0.02 0.02
PHAR
77GF Score
Pharming Group PHAR
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.12% mean?
Pharming Group (PHAR) has a Institutional Ownership of 0.12% as of Jul. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Pharming Group and its competitors.
Is Pharming Group's Institutional Ownership too high?
Pharming Group's current Institutional Ownership is 0.12%. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Institutional Ownership compare to VRTX and REGN?
Pharming Group's Institutional Ownership of 0.12% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Pharming Group and its competitors. Pharming Group's current Institutional Ownership is 0.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.45, compared to a current price of $13.47 — trading 6.8% below its estimated fair value. The current Institutional Ownership is 0.12%. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Pharming Group (PHAR), the current Institutional Ownership is 0.12% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.47 is trading 6.8% below its estimated GF Value™ of $14.45. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Institutional Ownership: 0.12%
  • GF Value™: $14.45 vs. price of $13.47 (6.8% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score

Get the complete analysis for PHAR

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.47
Price
$14.45
GF Value